Activin and Inhibin

KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization.In VitroThe inhibition rates were 15.33±1.46 (%) for H1299/WT-p53 cells, and 14.31±1.90 (%) for H1299/M175H-p53 cells when cells were treated with KCC009 at

KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of histone lysine demethylases KDM2A/7A , with an IC 50 of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl

KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of histone lysine demethylases KDM2A/7A , with an IC 50 of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl

KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC 50 of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases researchForm:SolidIC50&amp: Target:KDM2B 0.021 μM (IC 50 ).

KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC 50 of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases researchForm:SolidIC50&amp: Target:KDM2B 0.021 μM (IC 50 ).

KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC 50 of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases researchForm:SolidIC50&amp: Target:KDM2B 0.021 μM (IC 50 ).

KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC 50 of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases researchForm:SolidIC50&amp: Target:KDM2B 0.021 μM (IC 50 ).

KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC 50 of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases researchForm:SolidIC50&amp: Target:KDM2B 0.021 μM (IC 50 ).

KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC 50 of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases researchIC50&amp: Target:KDM2B 0.021 μM (IC 50 ).

KDM2B-IN-4 is a histone demethylase KDM2B inhibitor extracted from patent WO2016112284A1, compound 182b. KDM2B-IN-4 can be used for the research of cancerForm:SolidIC50&amp: Target:KDM2.

KDM2B-IN-4 is a histone demethylase KDM2B inhibitor extracted from patent WO2016112284A1, compound 182b. KDM2B-IN-4 can be used for the research of cancerForm:SolidIC50&amp: Target:KDM2.

KDM4-IN-2 (Compound 19a) is a potent and selective KDM4 / KDM5 dual inhibitor with K i s of 4 and 7 nM for KDM4A and KDM5B, respectivelyForm:SolidIC50&amp: Target:Ki: 4 nM (KDM4A ), 7 nM (KDM5B), IC50: 100±41 nM (KDM4A), 43±21 nM (KDM4B), 38 nM